biological source
goat
Quality Level
conjugate
FITC conjugate
antibody form
affinity purified immunoglobulin
antibody product type
secondary antibodies
clone
polyclonal
species reactivity
human
manufacturer/tradename
Chemicon®
concentration
1 mg/mL
technique(s)
ELISA: suitable, immunofluorescence: suitable
shipped in
wet ice
target post-translational modification
unmodified
General description
Antibody molecules typically comprise two immunoglobulin light chains covalently bound to a pair of heavy chains. Immunoglobulin light chains occur in two types, designated by the Greek letters kappa and lambda. Kappa and lambda light chains are approximately 250 amino acids in length with an average mass of about 25 kDa. The ratio of kappa to lambda found in the immunoglobulin population varies by species.
Immunogen
Epitope: Ig lambda chain
Prepared from pooled antisera from goats hyperimmunized with human myeloma proteins with lambda light chains.
Application
Goat anti-Human Ig λ chain Antibody, FITC conjugate is an antibody against Human Ig λ chain for use in ELISA & IF.
Immunofluorescence: ≤1 μg/106 cells.
ELISA:
Optimal working dilutions must be determined by the end user.
ELISA:
Optimal working dilutions must be determined by the end user.
Research Category
Secondary & Control Antibodies
Secondary & Control Antibodies
Research Sub Category
Fragment Specific Secondary Antibodies
Fragment Specific Secondary Antibodies
Biochem/physiol Actions
Reacts with human lambda light chains. Absorbed for human myeloma proteins with kappa light chains.
The antibody reacts with human lambda light chains as demonstrated by ELISA and flow cytometry.
Physical form
Affinity Chromatography
Purified by affinity chromatography on pooled human Igs with lambda light chains covalently linked to agarose. Liquid in 1.0 mL PBS/NaN3.
Preparation Note
Maintain refrigerated at 2°-8°C under sterile conditions for up to twelve months from date of receipt. Do not freeze.
Legal Information
CHEMICON is a registered trademark of Merck KGaA, Darmstadt, Germany
Disclaimer
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Still not finding the right product?
试用我们的 产品选型工具 工具缩小选择范围
wgk
WGK 2
flash_point_f
Not applicable
flash_point_c
Not applicable
存储类别
12 - Non Combustible Liquids
Joel G Turner et al.
Oncotarget, 7(48), 78896-78909 (2016-11-03)
Acquired proteasome-inhibitor (PI) resistance is a major obstacle in the treatment of multiple myeloma (MM). We investigated whether the clinical XPO1-inhibitor selinexor, when combined with bortezomib or carfilzomib, could overcome acquired resistance in MM. PI-resistant myeloma cell lines both in
全球贸易项目编号
| 货号 | GTIN |
|---|---|
| AP506F | 04053252740305 |